Results of the April 2016 Innovation Grants competition

We are pleased to announce the results of the most recent Innovation Grants competition to support unique and creative research ideas that will impact cancer. Below is a listing of newly awarded Canadian Cancer Society (CCS) Innovation Grants. 

Out of a total of 199 grant applications, 15 Canadian Cancer Society Innovation Grants have been approved – an 8% success rate. All grants have been awarded to a maximum budget of $200,000 with a maximum 3 year term. The 15 grants total almost $2.9 million in funding over the terms of these grants. 

Fewer grants were awarded than the 25 that were anticipated in this round. ACOR and CCSRI carefully consider the grants submitted across all of our funding programs and allocate funds to support the highest number of meritorious grants possible. Grants submitted to CCSRI's Innovation and Innovation to Impact (i2I) competitions are reviewed by the same set of panels, and funding recommendations are considered together. There was a very strong group of Innovation to Impact (i2I) applications in this round which resulted in a higher number of i2I grants being awarded (9 i2I grants totalling over $4 million, relative to 5 grants anticipated). 

Funds committed to this competition have been made possible by the significant efforts of Canadian Cancer Society volunteers and donors across the country. 

We would also like to acknowledge the Lotte & John Hecht Memorial Foundation who supported specific grants in this competition as indicated below.

We are also very pleased that all grants are being funded to their full panel recommended amounts and that no administrative decrements are being applied.

Summaries of awarded grants

Please note: 

  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment. 
  • The start date for these grants is August 1, 2016. 
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants. 
Note Carefully: 

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification. 

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Applicant
Institution
Title
Award
Barbera, Lisa
Sunnybrook Research Institute
What is the impact of a provincial program to screen for symptoms on health service use?
2016/2017 :  $66,226
2017/2018 :  $62,945
2018/2019 :  $64,246
Bratman, Scott
Princess Margaret Cancer Centre - UHN
Early detection of tumour response for adaptive therapy in oropharynx cancer
*Co-funded by the Lotte and John Hecht Memorial Foundation
2016/2017 :  $99,975
2017/2018 :  $99,975
Courneya, Kerry
University of Alberta
Exercise during neoadjuvant rectal cancer treatment: the EXERT trial
2016/2017 :  $19,553
2017/2018 :  $71,536
2018/2019 :  $40,250
Edelstein, Kim
Princess Margaret Cancer Centre - UHN
Does exercise improve progression-free survival in glioblastoma? A prospective single-arm intervention trial
2016/2017 :  $91,478
2017/2018 :  $64,830
2018/2019 :  $43,692
Fahlman, Richard
University of Alberta
The N-terminal program: a novel branch of N-terminal–dependent protein degradation that can destabilize large fractions of the cellular proteome
2016/2017 :  $99,471
2017/2018 :  $88,500
Ferguson, Sarah
Princess Margaret Cancer Centre - UHN
Targeting the immune microenvironment of microsatellite instable non-serous ovarian carcinoma
2016/2017 :  $100,000
2017/2018 :  $99,306
Lange, Philipp
University of British Columbia
Proteolytic protein termini as a new strategy for cancer cell–specific therapy
2016/2017 :  $99,297
2017/2018 :  $99,672
Rosen, Kirill
Dalhousie University
Exosomal Perp emission in response to targeted breast cancer therapy: diagnostic implications
2016/2017 :  $100,000
2017/2018 :  $100,000
Senger, Donna
University of Calgary
Targeting neutrophil recruitment in cancer metastasis
*Co-funded by the Lotte and John Hecht Memorial Foundation
2016/2017 :  $100,000
2017/2018 :  $100,000
Sidhu, Sachdev
University of Toronto
Manipulation of the erythropoietin signalling pathway by protein-engineered variants for anemia therapy in the oncology clinic
2016/2017 :  $100,000
2017/2018 :  $100,000
Stanford, William
Ottawa Hospital Research Institute
Inducing synthetic lethality in refractory acute myelogenous leukemia (AML)
2016/2017 :  $100,000
2017/2018 :  $100,000
Thibodeau, Jacques
Université de Montréal
Novel tumour suppressive functions of the MARCH1 E3 ubiquitin ligase
2016/2017 :  $65,640
2017/2018 :  $65,640
2018/2019 :  $65,640
Yamanaka, Yojiro
McGill University
Elucidating epithelial homeostasis in the oviduct/fallopian tube as cells of origin in high-grade serous ovarian cancer
2016/2017 :  $100,000
2017/2018 :  $100,000
Zadeh, Gelareh
The Toronto Hospital (Western Division) - UHN
Exploring the role of R/S-2HG as a biomarker for optimizing glioma resection and understanding glioma microenvironment heterogeneity
2016/2017 :  $80,000
2017/2018 :  $81,550
Zheng, Gang
Princess Margaret Cancer Centre - UHN
Nature-inspired smart nanoparticles for image-guided photodynamic therapy of head and neck cancer
*Co-funded by the Lotte and John Hecht Memorial Foundation
2016/2017 :  $100,000
2017/2018 :  $100,000

Last modified on: January 30, 2017